ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2012
Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies.Journal of clinical immunology · 2019Observational
- Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.Journal of neurovirology · 2016Article
- Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.PloS one · 2016Article
- JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.Journal of neurovirology · 2015Article
- Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.Journal of neurovirology · 2015Article
- Review
- Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.BMC neurology · 2014Article
- JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.Therapeutics and clinical risk management · 2014Article
- Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Journal of central nervous system disease · 2014Review
- Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2013Observational
- Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.Virology journal · 2013Observational
- JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.Journal of translational medicine · 2012Article
- BG-12 and its potential for the prevention of relapse in multiple sclerosis.Degenerative neurological and neuromuscular disease · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab for multiple sclerosis (MS) is a serious concern. The presence of anti-JC virus antibodies is a risk factor for PML development, but 2.5 % of the patients result falsely-negative, while the prognostic relevance of testing JCV-DNA in biological fluids of treated patients is debated. Aim of this work was to evaluate the utility of testing JCV-DNA, together with anti-JCV antibodies, in biological samples of treated patients as a tool for PML risk stratification. 126 subjects from 5 MS Centers in Italy were included in the study. We performed a cross-sectional study in 63 patients testing JCV-DNA in blood, peripheral blood cells and urine. We longitudinally assessed the presence of JCV-DNA in a cohort of 33 subjects, one of which developed PML. We could test retrospectively serum samples from another PML case occurred during natalizumab therapy. Anti-JCV antibodies and urinary JCV-DNA were both tested in 73 patients. No changes in JCV-DNA status occurred during natalizumab treatment. The subject who developed PML in the longitudinal cohort had detectable JCV-DNA in urine at all time-points while serum or blood from both PML patients were always negative before the onset of disease and, in one case, after. Four subjects with JCV-DNA in urine and undetectable anti-JCV antibodies were retested for anti-JCV antibodies and three out of four resulted positive. In conclusion, testing JCV-DNA in urine is complementary to testing anti-JCV antibodies in identifying patients at risk of PML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.